D-0862-2020 Class II Terminated
FDA drug recall D-0862-2020 was initiated by Teva Pharmaceuticals USA on Feb 20, 2020 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing. The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 3,695 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Feb 20, 2020
- Termination Date
- Oct 6, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,695 bottles
Product description
Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054; NDC 0591-2245-22.
Reason for recall
Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.
Distribution pattern
Nationwide in the USA.
Code information
Lot #: 1342500A, Exp 10/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0862-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026